Popular works in the category explore 340B guidelines, ‘smart pharma’ capabilities, and commercialization trends.
The most-viewed articles in the manufacturing and packaging space add plenty of value, due to their ability to intersect other areas in the pharma space, whether it be regulatory developments or product commercialization.
Below are the top 3 manufacturing and packaging works of the year.
3. A 340B Navigation Guide for Pharmaceutical Manufacturers
The 340B program requires pharma manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to eligible healthcare organizations, referred to as covered entities (CEs). With 340B's rapid growth and impact, drug manufacturers must explore ways to improve their data management and pricing processes to sustain their business, while also providing discounted medications to those in need.
2. Advancing ‘Smart Pharma’ Capabilities in 2023 and Beyond
Pharmaceutical Commerce connected with Samantha Betancourt, head of strategy and marketing at UPS Healthcare, to discuss the pathway for smart pharma—a term which includes the application of smarter data management and storage methods, to the increased use of data automation to offset strained resources in manufacturing and distribution—in helping address current and future supply chain challenges.
1. Channel Fragmentation and Diversifying Product Archetypes
Twenty years ago, Blue Fin Group saw a phenomenon developing that changed how products were commercialized depending on their “product archetype.” Fast forward to today, the company tracks and analyzes 10 archetypes—traditional brand, generic, vaccine, specialty lite, specialty generic, biosimilar, specialty (self-administration and healthcare provider administration), orphan and rare, cell and gene, and digital. When developing commercialization strategies, we separate and segment these archetypes because the payers, providers, pharmacies, patients, and physical flows are significantly different for each one.